Market Performance Overview
As of February 25, 2026, Amgen Inc. (ticker symbol: AMGN) demonstrated notable performance in the U.S. stock market. The stock opened at $381.50, reached a high of $387.49, and a low of $380.54, closing at $384.33. This closing price represents an increase of $1.46 from the previous close of $382.87, resulting in a percentage change of approximately 0.38%. The trading volume for the day was approximately 9.43 million shares.
The stock showed resilience and upward momentum, supported by recent strong financial results. Amgen reported a significant revenue increase in its Q4 2025 earnings, with revenues reaching $9.87 billion, surpassing analysts' expectations. This positive financial outlook helped boost investor confidence, leading to a notable increase in the stock price over recent weeks.
On February 3, 2026, Amgen announced its Q4 results, which included an adjusted earnings per share (EPS) of $5.29, exceeding the consensus estimate of $4.76. The strong performance was driven by robust sales of key products such as Repatha and Evenity. Additionally, the company provided an optimistic forecast for 2026, projecting revenues between $37 billion and $38.4 billion and adjusted EPS ranging from $21.60 to $23.
News and Developments
- 52-Week High Achievement: On February 25, 2026, Amgen's stock reached a new 52-week high of $387.49, reflecting strong investor sentiment and positive market performance. This milestone highlights the company's solid fundamentals and growth prospects.
- Outperforming Major Indices: Reports indicate that Amgen's stock outperformed the Dow Jones Industrial Average on the day. This relative strength compared to broader market indices may attract additional investor interest and confidence.
- Acquisition and Pipeline Developments: Amgen's recent acquisition of Dark Blue Therapeutics has strengthened its oncology pipeline, enhancing future growth potential. The company continues to focus on innovative therapeutics targeting serious diseases, aligning with its long-term strategic goals.
- Regulatory Approvals: Amgen recently received European Commission approval for UPLIZNA (inebilizumab) as a treatment for generalized myasthenia gravis. This regulatory milestone is expected to expand Amgen’s market presence and product offerings in the neurology sector, contributing positively to revenue streams.
- Market Sentiment and Analyst Ratings: Financial analysts have maintained positive outlooks on Amgen, with many issuing "buy" ratings based on the company’s strong earnings outlook and robust product pipeline. Recent performance and strategic moves have increased analyst coverage and investor attention.
Conclusion
Amgen Inc. exhibited a robust market performance on February 25, 2026, closing at $384.33 after reaching a new 52-week high. The company’s strong Q4 2025 financial results, favorable regulatory developments, and strategic acquisitions have all played key roles in supporting its strong market position. With a promising outlook for 2026, highlighted by expected revenue growth and continued innovation in its product pipeline, Amgen remains a significant player in the competitive biotechnology sector. Market participants will likely continue to monitor the company’s performance closely as it pursues long-term growth objectives.
Explore more exclusive insights at nextfin.ai.
